---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-116327"
form_type: "8-K"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:31:58.078601+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Barinthus Bio presents interim Phase 2b HBV003 and Phase 2a AB-729-202 data for VTP-300 in chronic HBV at AASLD

## Summary
- In HBV003, 31% of participants with screening HBsAg ≤200 IU/mL had >1 log HBsAg reductions.
- In AB-729-202, all VTP-300 treated patients maintained HBsAg <100 IU/mL through week 48; 60% maintained <10 IU/mL.
- Seven HBV003 participants met criteria for NUC discontinuation; three discontinued NUC therapy.
- No treatment-related serious adverse events were reported in either trial.
- Data presented in collaboration with Arbutus Biopharma (ABUS) for imdusiran plus VTP-300 combination.

## SEC filing metadata
- accession: 0001104659-23-116327
- form_type: 8-K
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000110465923116327/0001104659-23-116327-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000110465923116327/tm2330270d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-116327
- JSON: https://secwatch.observer/filing/0001104659-23-116327.json
- Plain text: https://secwatch.observer/filing/0001104659-23-116327.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.